Corvus Pharmaceuticals, Inc. (CRVS) Stock

Corvus Pharmaceuticals, Inc. (CRVS) is a Healthcare stock trading at $11.91 (as of 2026-06-18), with a market capitalization of $1.04B and a trailing P/E of -21.7. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing immuno-oncology therapies, including Mupadolimab (anti-CD73) and CPI-818 (ITK covalent inhibitor), as well as Ciforadenant (A2A receptor antagonist), with additional preclinical candidates such as CPI-182 and CPI-935. Its pipeline is aimed at treating cancers including non-small cell lung cancer, head and neck cancers, malignant T-cell lymphomas, and renal cell cancer.

Valuation — source: SEC EDGAR (first-party)
Price	$11.91
Market Cap	$1.04B
P/E Ratio	-21.7
EV / EBITDA	-20.1
Price / Book	4.17
Dividend Yield	0.0%
DCF Value (model)	$-6.63
DCF Upside vs Price	-155.7%

Profitability & Growth — source: SEC EDGAR
Return on Equity	-18.4%
Current Ratio	19.81

Valuation vs Sector & Industry
Stock P/E	-21.7
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-203.8%
vs Industry	-227.5%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	ORBIMED ADVISORS LLC ($104.82M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Richard A. Miller
Employees	31
Country	US
IPO Date	2016-03-23

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.